Risk Factors for Development of Cirrhosis in Chronic Viral Hepatitis B Patients Who Had Persistent Viral Suppression With Antiviral Therapy

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2024 Mar 25

PMID 38523735

Authors

Soe T Maung

Pakanat Decharatanachart

Sombat Treeprasertsuk

Roongruedee Chaiteerakij

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Chronic viral hepatitis B (CHB)-infected patients occasionally develop cirrhosis despite having persistent viral suppression with antiviral therapy. We aimed to identify risk factors for developing cirrhosis in hepatitis B virus (HBV)-suppressed patients.

Methods: We conducted a case-control study involving 120 noncirrhotic CHB-infected patients achieving viral suppression with antiviral treatment, with 40 cases developing cirrhosis and 80 age-, sex-, and Fibrosis-4 (FIB-4)-matched controls. Clinical and laboratory data at viral suppression, including body mass index (BMI), comorbidities, pretreatment HBV viral load, HBe antigen status, hepatitis C virus (HCV) and HIV coinfections, liver chemistries, and AST to Platelets Ratio Index (APRI) values, were retrospectively abstracted. Risk factors for cirrhosis post-HBV suppression were identified using Cox proportional hazard analysis.

Results: Case and control groups had similar ages (51.4 ± 9.9 vs. 51.4 ± 10.2 years), proportions of males (80% vs. 80%), and FIB-4 values (1.32 vs. 1.31). The cirrhosis group showed significantly higher BMI (25.1 vs. 22.7, = 0.01) and more diabetes prevalence (50.0% vs. 26.3%, = 0.01), while other comorbidities and laboratory parameters were comparable ( > 0.05). By univariate analysis, BMI >23 kg/m2, diabetes, and APRI >0.7 were significantly associated with cirrhosis, with hazard ratios (HRs) (95%CI) of 2.99 (1.46-6.13), 2.31 (1.23-4.36), and 2.71 (1.05-6.99), = 0.003, 0.010, and 0.039, respectively. In multivariate analyses adjusted for APRI, BMI>23 kg/m remained significantly associated with cirrhosis (aHR: 2.76, = 0.006), while diabetes showed borderline significance (aHR: 1.99, = 0.072).

Conclusions: In HBV-infected patients achieving viral suppression with therapy, a BMI >23 kg/m increases the risk of cirrhosis. Therefore, a comprehensive approach addressing metabolic factors is imperative for preventing disease progression in HBV-infected patients.

References

Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm S, Christensen E . Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97(11):2886-95. DOI: 10.1111/j.1572-0241.2002.07057.x. View

Chang T, Gish R, de Man R, Gadano A, Sollano J, Chao Y . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10):1001-10. DOI: 10.1056/NEJMoa051285. View

Wong G, Wong V, Choi P, Chan A, Chim A, Yiu K . Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2008; 58(1):111-7. DOI: 10.1136/gut.2008.157735. View

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

de Ledinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B . Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013; 37(10):979-88. DOI: 10.1111/apt.12307. View

Tran T, Martin P . Hepatitis B: epidemiology and natural history. Clin Liver Dis. 2004; 8(2):255-66. DOI: 10.1016/j.cld.2004.02.008. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2001; 34(6):1225-41. DOI: 10.1053/jhep.2001.29401. View

Chang T, Liaw Y, Wu S, Schiff E, Han K, Lai C . Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52(3):886-93. DOI: 10.1002/hep.23785. View

Yu M, Shih W, Lin C, Liu C, Jian J, Tsai K . Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008; 26(34):5576-82. DOI: 10.1200/JCO.2008.16.1075. View

10.

Chon Y, Jung K, Ha Y, Kim M, Lee J, Hwang S . High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. J Viral Hepat. 2020; 27(11):1119-1126. DOI: 10.1111/jvh.13345. View

11.

. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. DOI: 10.1016/j.jhep.2012.02.010. View

12.

Huo T, Wu J, Hwang S, Lai C, Lee P, Tsay S . Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol. 2000; 12(6):687-93. DOI: 10.1097/00042737-200012060-00019. View

13.

Udompap P, Tanwandee T, Gani R . Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes. Clin Liver Dis (Hoboken). 2021; 16(6):249-253. PMC: 7805294. DOI: 10.1002/cld.977. View

14.

Schiff E, Lee S, Chao Y, Yoon S, Bessone F, Wu S . Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2010; 9(3):274-6. DOI: 10.1016/j.cgh.2010.11.040. View

15.

Chen Y, Chen H, Wang T, Chang C, Chang C, Chen W . The dissociation between the diabetes and both Child-Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic. Hepatol Int. 2011; 5(4):955-64. DOI: 10.1007/s12072-011-9274-y. View

16.

Kim S, Lee J, Kim D, Ahn S, Jung K, Choi E . Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 2012; 7(5):e36676. PMC: 3344942. DOI: 10.1371/journal.pone.0036676. View

17.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

18.

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

19.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

20.

Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M . High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001; 34(4 Pt 1):738-44. DOI: 10.1053/jhep.2001.28055. View